Market Newsdesk

SAN DIEGO
, Aug. 5, 2025 /PRNewswire/ — Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, the premier U.S. sexual wellness industry event. The award will be presented today, August 5, 2025, during the conference held in Nashville, Tennessee.

The STIMULATE Conference is North America’s only trade show and leadership summit focused exclusively on sexual wellness, innovation, and empowerment. This year, Saundra Pelletier will be recognized alongside an elite group of female founders who are redefining what it means to lead in spaces historically overlooked — especially when it comes to reproductive health, autonomy, and the language we use to discuss them.

This honor is especially meaningful as it falls during Say Vagina Month— a bold public initiative launched by Evofem to end the shame and censorship surrounding vaginal health and advocate for medically accurate, empowering language in healthcare and social discourse.

“When we talk about birth control, the message is almost always fear-based,” said Saundra Pelletier. “But let’s be honest: if we’re using birth control, it’s because of sex. So, let’s talk about sex. Let’s talk about satisfaction. Let’s talk about pleasure. Because women deserve more than prevention — they deserve agency, honesty, and joy in the conversation. That’s what this award means to me.”

Evofem engages healthcare providers on the importance of addressing sexual satisfaction as part of their contraceptive counseling, leveraging compelling data published in the Journal of Sexual Medicine.  The data demonstrate that nearly 90% of women using Evofem’s hormone-free contraceptive, PHEXXI® (lactic acid, citric acid, and potassium bitartrate), improved or maintained their level of sexual satisfaction in the Phase 3 AMPOWER trial.

As a company led by women and committed to empowering women through science, advocacy, and access, Evofem views this recognition as not just an award — but a call to keep pushing forward.

About Evofem Biosciences

Evofem is commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

• PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.  
• SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. 

Evofem’s commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the U.S. The Company is entering global markets through strategic partnerships, including a license agreement for the Middle East and North Africa under which PHEXXI and SOLOSEC are expected to launch in the UAE in 2026.

As previously announced, Evofem entered into a definitive agreement to be acquired by Aditxt, Inc. (Nasdaq: ADTX). Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, Inc., as amended (the “A&R Merger Agreement”), Aditxt aims to add a dedicated to women’s health program to its social innovation platform accelerating promising health innovations. The companies are working toward a targeted close in the second half of 2025.

PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

Forward-Looking Statements

This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. The closing of the transaction with Evofem, Aditxt and Adifem, Inc., under the A&R Merger Agreement, as amended, is subject to several conditions including, but not limited to, 1) approval of the transaction by a majority of the combined voting power of Evofem’s E-1 and Common Stock, voting together as a single class, at a meeting where quorum is present, and 2) Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15 million required to satisfy Evofem’s senior secured noteholder. Should Aditxt fail to secure these funds, Evofem’s senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.  You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

Contact

Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
[email protected]
(917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-ceo-saundra-pelletier-honored-with-trailblazing-female-founders-award-at-stimulate-conference-302521900.html

SOURCE Evofem Biosciences, Inc.

MarketNewsUpdates


News Commentary

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Experts following the Global Radar Systems market are optimistic about what AI can do to this market. According to a report from MarketsAndMarkets said that the integration of Artificial Intelligence (AI) into radar systems is revolutionizing the way we perceive and interact with the world. From enhancing signal processing capabilities to enabling autonomous decision making, AI is transforming radar technology across various sectors, including defense, aviation, automotive, and weather forecasting. The Radar Systems Industry is driven by factors such as increasing adoption of radar systems in Defense & commercial aircrafts, marine vessels, weather stations, airport surveillance, unmanned vehicles, satellites, etc.  The report said: “Traditional radar systems rely on predefined algorithms to process signals, which can be limited in dynamic environments. AI introduces adaptive signal processing techniques that enhance the radar’s ability to detect and interpret signals amidst noise and clutter. Machine learning models can learn from vast datasets to identify patterns and anomalies, improving target detection accuracy. For instance, AI algorithms can enhance the signal to noise ratio, enabling the detection of weak signals that might be overlooked by conventional methods.

Additionally, AI can facilitate real time clutter suppression, ensuring that irrelevant echoes do not hinder the radar’s performance. Adaptive thresholding using machine learning allows radar systems to adjust their sensitivity based on environmental conditions, further optimizing performance. Moreover, AI enhances Doppler signal interpretation, aiding in the accurate measurement of target velocity. By classifying radar echoes via neural networks, systems can differentiate between various objects, such as distinguishing a bird from a drone. Real time AI based pulse compression and interference mitigation ensure that radar systems maintain high resolution and accuracy even in challenging scenarios. Pattern recognition in complex environments and AI support in analog to digital conversion further underscore the transformative impact of AI on radar signal processing.”  Active Companies in the markets today include VisionWave Holdings Inc. (NASDAQ: VWAV), Archer Aviation Inc. (NYSE: ACHR), Rocket Lab Corporation (NASDAQ: RKLB), Joby Aviation, Inc. (NYSE: JOBY), Sidus Space (NASDAQ: SIDU).

MarketsAndMarkets continued: “In defense and security applications, the ability to autonomously detect and recognize threats is paramount. AI enhances radar systems by enabling automatic target recognition (ATR), allowing systems to identify objects without human intervention. Through machine learning, radar systems can differentiate between friend or foe, reducing the risk of friendly fire incidents. Neural networks facilitate multi target tracking, enabling the monitoring of multiple objects simultaneously. AI enhanced object classification in Synthetic Aperture Radar (SAR) imagery allows for detailed analysis of terrain and structures. Learning algorithms contribute to adaptive threat modeling, enabling systems to predict and respond to evolving threats. Contextual interpretation of radar scenes ensures that systems understand the environment, enhancing situational awareness. By reducing false positives in hostile environments, AI improves the reliability of threat detection. Combining Electro Optical/Infrared (EO/IR) and radar data using AI provides a comprehensive view of the battlefield. Predictive analytics for potential target behavior and real time tracking in dense threat scenarios further demonstrate AI’s role in enhancing radar-based threat detection and recognition.”

VisionWave (NASDAQ: VWAV) – Leading Live-Fire Radar Demonstration with Major Abu Dhabi Defense Partner Highlighting Next-Generation Technology and Showcasing Defense Capabilities – VisionWave Holdings Inc. ($VWAV), a next-generation defense technology company specializing in AI-powered sensing and autonomous threat response systems, today announced it plans to lead a high-profile live-fire demonstration of its super-resolution radar system in September 2025. The strategic trial will be conducted in collaboration with a leading government-owned defense contractor in Abu Dhabi, United Arab Emirates.

The radar system—part of VWAV’s advanced sensing suite for tactical Active Protection Systems (APS)—was chosen following rigorous competitive evaluations against several top-tier global radar solutions. The upcoming live-fire event is designed to replicate a spectrum of complex aerial threat scenarios, varying in size, speed, and radar cross-section, to rigorously assess the radar’s detection and tracking performance under realistic battlefield conditions.

“This live-fire trial represents far more than a technical validation—it is set to become a defining milestone for VisionWave,” said Noam Kenig, Chief Executive Officer of VisionWave. “Our AI-powered super-resolution radar is engineered to detect, classify, and track high-speed threats with real-time precision. Being selected by a top-tier global defense partner for this live-fire demonstration underscores what we believe is VWAV’s technological advantage. At the core of our mission is a singular focus: saving lives by delivering accurate, dependable threat detection in the most challenging battlefield conditions.”

Confirming VisionWave’s Role in Next-Generation Defense –
The radar systems slated for the demonstration were purchased directly by the Abu Dhabi defense partner as part of a broader integration and evaluation phase. During the live-fire exercise VWAV’s technology will be tested in operationally realistic, high-intensity scenarios to determine its effectiveness within layered defense architectures—where early detection is critical to enabling timely countermeasures deployment.

Backed by Strong Capital for Global Expansion –
VisionWave has recently secured a strategic funding facility of up to $50 million, including an initial $5 million tranche commitment, strengthening the Company’s ability to access growth capital. With this enhanced financial foundation and public market presence, VWAV’s leadership believes the Company is well-positioned to accelerate development milestones, support large-scale defense programs, and meet the growing demand for next-generation defense technologies across the U.S., UAE, and allied nations.

Positioned for Strategic Growth in a High-Demand Sector
– This initiative is a key step in VWAV’s strategic roadmap to become a mission-critical technology provider for AI-enabled battlefield autonomy and advanced defense systems. The Company’s super-resolution radar platform driven by proprietary AI algorithms is engineered to deliver real-time, high-precision detection, classification, and tracking of fast-moving threats, addressing critical requirements in next-generation active defense architectures.  Continued…  Read this full release and additional news for VWAV by visiting:  https://finance.yahoo.com/quote/VWAV/news/

Other recent developments in the Defense & Military industries include:

Archer Aviation Inc. (NYSE: ACHR) recently announced the successful completion of an initial flight of its Midnight aircraft at Al Bateen Executive Airport in Abu Dhabi, marking a key milestone for its planned commercial deployment in the UAE and the expansion of its operations in the Middle East region.

With the support of the Smart and Autonomous Systems Council (SASC), the flight was witnessed by senior leadership from the UAE General Civil Aviation Authority (GCAA), the Abu Dhabi Investment Office (ADIO), the Integrated Transport Centre, Abu Dhabi Aviation and Abu Dhabi Airports, along with representatives from Archer’s regional partners. Focused on evaluating the aircraft’s VTOL performance in UAE-specific conditions including temperature, humidity and dust exposure, the test flight allows Archer to validate readiness for commercial deployment.

Rocket Lab Corporation (NASDAQ: RKLB) recently announced the launch window for its next mission for multi-launch customer, Institute for Q-shu Pioneers of Space, Inc. (iQPS), a Japan-based Earth imaging company – marking Electron’s 69th mission to date and 11th launch this year.

The mission, named ‘The Harvest Goddess Thrives’, is scheduled to launch from Rocket Lab Launch Complex 1 in New Zealand during a launch window that opens on August 5, 2025 UTC. The mission will deploy QPS-SAR-12, nicknamed KUSHINADA-I for the Japanese goddess of harvest and prosperity, to a 575km circular Earth orbit to join the rest of the QPS-SAR constellation in providing high resolution synthetic aperture radar images and Earth monitoring services globally.

Joby Aviation, Inc. (NYSE: JOBY) and L3Harris Technologies (LHX) recently announced they are exploring opportunities to develop a new aircraft class for defense applications. The gas turbine hybrid vertical take-off and landing (VTOL) aircraft is designed for low-altitude missions and offers the versatility of being optionally piloted, enabling both crewed and fully autonomous operations.

The collaboration leverages Joby’s existing commercial aircraft development program and leading manufacturing capabilities, combined with L3Harris’ proven expertise on platform missionization including sensors, effectors, communication and collaborative autonomy. Flight testing is expected to start this fall with the companies planning to perform operational demonstrations during government exercises in 2026.

“The next-generation of vertical lift technology enables long-range, crewed-uncrewed teaming for a range of missions,” said Jon Rambeau, President, Integrated Mission Systems, L3Harris. “We share a vision with Joby to deliver urgently-required innovation by missionizing VTOL aircraft for defense needs.”

Sidus Space
(NASDAQ: SIDU) recently announced the successful deployment of its new autonomous guidance, navigation, and control (GNC) software, SpacePilot and commissioning of the Attitude Determination and Control System (ADCS) on LizzieSat^®-3 (LS3).

“Activating SpacePilot and commissioning the ADCS marks a critical milestone for LS3’s mission,” said Carol Craig, Founder and CEO of Sidus Space. “This software enables a higher level of autonomy, ensuring greater efficiency and mission resilience while reducing reliance on ground resources.”

The successful commissioning of the ADCS marks a critical step toward LS3’s full mission readiness. With the deployment of autonomous SpacePilot, the satellite can achieve accurate sun-pointing for maximum power generation, stabilize payload orientation for improved data collection, and maintain antenna alignment for reliable communications. This milestone also paves the way for more rapid commissioning of the remaining onboard technologies, including Sidus’s proprietary sensor suite.

DISCLAIMER:  MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  MNU is NOT affiliated in any manner with any company mentioned herein.  MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  MNU’S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  MNU is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed MNU has been compensated forty nine hundred dollars for news coverage of the current press releases issued by VisionWave Holdings, Inc. by the Company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information:

Media Contact email: [email protected] – +1(561)486-1799

Logo – https://mma.prnewswire.com/media/2737336/5444984/MarketNewsUpdates.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/how-artificial-intelligence-is-disrupting-radar-systems-designed-for-military-defense-ops-302521223.html

SOURCE MarketNewsUpdates

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Sable Offshore Corp. (“Sable Offshore Corp.” or the “Company”) (NYSE: SOC) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sable Offshore Corp. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons or entities who purchased or otherwise acquired publicly traded Sable Offshore securities between May 19, 2025 and June 3, 2025, inclusive, and/or pursuant and/or traceable to the Company’s May 21, 2025 secondary public offering. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/sable-offshore-corp-lawsuit-submission-form?prid=159579&wire=4 

SOC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants represented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not; and (2) as a result, defendants statements about Sables business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

WHAT’S NEXT? If you suffered a loss in Sable Offshore Corp. during the relevant time frame, you have until September 26, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected] 
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lost-money-on-sable-offshore-corpsoc-join-class-action-suit-seeking-recovery–contact-levi–korsinsky-302521397.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form-3?prid=159581&wire=4

NVO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Novo’s growth potential; notably, that its asserted potential to capitalize on the compounded market greatly understated the potential impact of the personalization exception to the compounded GLP-1 exclusion and overstated the likelihood such patients would switch to Novo’s branded alternatives, and further greatly overstated the potential GLP-1 market or otherwise Novo’s capability to penetrate said markets to achieve continued growth.   On July 29, 2025, Novo announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The Company attributed the guide down on “lowered growth expectations for the second half of 2025” for both Wegovy and Ozempic due to “the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition.”  Following this news, the price of Novo’s common stock declined dramatically. From a closing market price of $69.00 per share on July 28, 2025, Novo’s stock price fell to $53.94 per share on July 29, 2025, a decline of about 21.83% in the span of just a single day.

WHAT’S NEXT? If you suffered a loss in Novo during the relevant time frame, you have until September 30, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lost-money-on-novo-nordisk-asnvo-join-class-action-suit-seeking-recovery–contact-levi–korsinsky-302521401.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Lockheed Martin Corporation (“Lockheed Martin Corporation” or the “Company”) (NYSE: LMT) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Lockheed Martin Corporation investors who were adversely affected by alleged securities fraud between January 23, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/lockheed-martin-corporation-lawsuit-submission-form?prid=159580&wire=4

LMT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reporting of its risk adjusted profit booking rate; (2) Lockheed Martin lacked effective procedures to perform reasonably accurate comprehensive reviews of program requirements, technical complexities, schedule, and risks; (3) Lockheed Martin overstated its ability to deliver on its contract commitments in terms of cost, quality and schedule; (4) as a result, the Company was reasonably likely to report significant losses; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in Lockheed Martin Corporation during the relevant time frame, you have until September 26, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-shareholders-of-lockheed-martin-corporationlmt-of-a-class-action-lawsuit-and-an-upcoming-deadline-302521406.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Neogen Corporation (“Neogen Corporation” or the “Company”) (NASDAQ: NEOG) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neogen Corporation investors who were adversely affected by alleged securities fraud between January 5, 2023 and June 3, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/neogen-corporation-lawsuit-submission-form?prid=159573&wire=4

NEOG investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the filed complaint, defendants issued a series of materially false and misleading statements which led investors to believe that the integration with the Food Safety Division of the 3M Company was progressing much better than it actually was. In addition, even when the Company was forced to reveal that certain “inefficiencies” arose as a result of the integration, defendants downplayed them and assured investors that they were fully aware and committed to resolving them quickly.

WHAT’S NEXT? If you suffered a loss in Neogen Corporation during the relevant time frame, you have until September 16, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-neogen-corporation-investors-of-a-class-action-lawsuit-and-upcoming-deadline–neog-302521079.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Flywire Corporation (“Flywire Corporation” or the “Company”) (NASDAQ: FLYW) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Flywire Corporation investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/flywire-corporation-lawsuit-submission-form?prid=159578&wire=4

FLYW investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the strength and sustainability of Flywire’s revenue growth was overstated; (ii) the negative impact that permit- and visa-related restrictions were having and were likely to have on Flywire’s business was understated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Flywire Corporation during the relevant time frame, you have until September 23, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-23-2025-in-flywire-corporation-lawsuit–flyw-302521409.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=159572&wire=4

CAPR investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.

WHAT’S NEXT? If you suffered a loss in Capricor during the relevant time frame, you have until September 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-notifies-shareholders-of-capricor-therapeutics-inccapr-of-a-class-action-lawsuit-and-an-upcoming-deadline-302521074.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in RxSight, Inc. (“RxSight, Inc.” or the “Company”) (NASDAQ: RXST) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/rxsight-inc-lawsuit-submission-form?prid=159576&wire=4

RXST investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company was experiencing “adoption challenges” and/or structural issues resulting in declines in sales and utilization; (2) defendants had overstated the demand for RxSight’s products; (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT’S NEXT? If you suffered a loss in RxSight, Inc. during the relevant time frame, you have until September 22, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi–korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-22-2025-in-rxsight-inc-lawsuit–rxst-302521391.html

SOURCE Levi & Korsinsky, LLP

NEW YORK
, Aug. 5, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. (“Alto Neuroscience, Inc.” or the “Company”) (NYSE: ANRO) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Alto Neuroscience, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/alto-neuroscience-inc-lawsuit-submission-form?prid=159574&wire=4

ANRO investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT’S NEXT? If you suffered a loss in Alto Neuroscience, Inc. during the relevant time frame, you have until September 19, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-alto-neuroscience-incanro-urged-to-join-class-action–contact-levi–korsinsky-to-learn-more-302521082.html

SOURCE Levi & Korsinsky, LLP